Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
Jones Mitchell Lawrence reported multiple insider transaction types in a Form 4 filing for PALI. The filing lists transactions totaling 17,989 shares at a weighted average price of $1.75 per share. Following the reported transactions, holdings were 13,263 shares.
Finley John David reported multiple insider transaction types in a Form 4 filing for PALI. The filing lists transactions totaling 30,562 shares at a weighted average price of $1.75 per share. Following the reported transactions, holdings were 27,353 shares.
Palisade Bio, Inc. received an amended Schedule 13G/A from Deep Track Capital and related entities reporting that they now beneficially own 0 shares, or 0.00%, of the company’s common stock as of December 31, 2025.
Deep Track Capital, Deep Track Biotechnology Master Fund, Deep Track Special Opportunities Fund and David Kroin each report no voting or dispositive power over any Palisade Bio shares. The filing notes that the ownership calculation is based on 149,003,210 shares outstanding as of November 5, 2025, as disclosed in Palisade Bio’s prior quarterly report.
Jones Mitchell Lawrence reported acquisition or exercise transactions in this Form 4 filing.
Palisade Bio Chief Medical Officer Mitchell Lawrence Jones was granted 787,000 restricted stock units on February 9, 2026. Each RSU represents a contingent right to receive one share of Palisade Bio common stock, though the units may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan.
The RSUs are scheduled to vest as to 1/6 of the award on July 6, 2026, with the remaining portions vesting quarterly over the following 10 quarters. Vesting depends on Jones maintaining continuous service with the company through each vesting date.
Palisade Bio, Inc. reported that CEO and CFO Finley John David acquired a grant of 2,011,000 Restricted Stock Units (RSUs) on February 9, 2026. Each RSU represents a right to receive one share of common stock, though the RSUs may be settled in cash until sufficient shares are reserved under the 2021 Equity Incentive Plan.
The RSUs will vest as to one-sixth of the units on July 6, 2026 and then vest quarterly over the following 10 quarters, conditioned on Finley’s continuous service with the company through each vesting date. Following this grant, he directly holds 2,011,000 derivative securities in the form of RSUs.
Palisade Bio, Inc. received a new large shareholder disclosure from Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia. The group reports beneficial ownership of 9,567,898 shares of Palisade Bio common stock, representing 6.4% of the outstanding class.
The ownership is held through Octagon Investments Master Fund, with Octagon acting as investment manager and Ting Jia as the control person of Octagon. The filing states the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Palisade Bio.
Palisade Bio, Inc. received a Schedule 13G from Franklin Resources affiliates reporting a passive ownership position in its common stock. As of December 31, 2025, Franklin Advisers, Inc. is reported as having sole voting and dispositive power over 9,163,990 shares of common stock, representing 6.0% of the class. This total includes 4,071,428 shares issuable upon exercise of warrants.
The securities are held for investment management clients of Franklin Resources’ investment management subsidiaries, which have the right to receive dividends and sale proceeds. Charles B. Johnson and Rupert H. Johnson, Jr. are included as reporting persons but each reports beneficial ownership of 0 shares and the filing states that Franklin Resources, the principal shareholders and subsidiaries disclaim pecuniary interest and beneficial ownership beyond what is required for reporting. The filers certify the holdings are in the ordinary course of business and not for changing or influencing control of Palisade Bio.
Palisade Bio director Donald Allen Williams reported a purchase of company stock. On January 16, 2026, he bought 5,000 shares of common stock at a price of $1.6712 per share, increasing his direct holdings to 10,728 shares.
In addition to his direct ownership, the filing shows an indirect holding of 3,000 common shares through the reporting person's defined benefit plan. This Form 4 reflects insider activity by a company director, providing transparency about changes in his ownership stake.
Palisade Bio, Inc. director Donald Allen Williams reported buying 5,000 shares of common stock on January 9, 2026 at a price of $1.88 per share. After this open-market purchase, he directly owns 5,728 common shares and has an additional 3,000 shares reported as indirectly owned through the reporting person's defined benefit plan.
Palisade Bio, Inc. filed a Form S-8 registering 236,557 shares of common stock for issuance to employees, directors, contractors, and consultants under its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The filing uses General Instruction E to add shares to previously registered plan securities and, under Rule 429, a combined prospectus will cover these and prior plan registrations.
As context, the company previously registered an aggregate 129,259 shares for the same plans across earlier S-8 filings. All share amounts in this filing reflect the 1-for-50 reverse split effective November 16, 2022 and the 1-for-15 reverse split effective April 5, 2024.